LGND

Business Context and Reporting Period

Company: Ligand Pharmaceuticals Incorporated
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Ligand is a biotechnology company focused on drug discovery and early-stage development. Its strategy relies on generating revenue through royalties from marketed products (AVINZA, PROMACTA) and milestone/collaborative payments from partnerships with major pharmaceutical companies (GSK, Pfizer, Merck, BMS). The company does not have manufacturing facilities and relies on third parties.

Key Financial Metrics

Note: 2007 Net Income includes significant gains from discontinued operations (sale of Oncology and AVINZA product lines). 2008 Loss includes a $72.0 million write-off of acquired in-process R&D from the Pharmacopeia acquisition.

Material Changes vs. Prior Period

• Revenue Composition Shift: Royalty revenue decreased by 59% ($12.0 million) primarily due to a contractual reduction in the AVINZA royalty rate from 15% to 5% in October 2008. This was offset by a significant increase in Collaborative R&D revenue ($23.6 million increase), driven by the acquisition of Pharmacopeia in late 2008.
• Operating Expenses: R&D expenses increased to $39.9 million (from $30.8 million) due to costs associated with servicing collaboration agreements ($21.2 million). General and Administrative expenses decreased to $15.2 million (from $23.8 million) due to reduced legal fees and headcount.
• One-Time Items: The company recorded $15.2 million in lease termination costs in 2009 related to exiting its San Diego corporate facility. Conversely, it recognized $21.9 million in accretion of deferred gain on a sale-leaseback transaction due to the lease termination.
• Acquisitions: Completed the acquisition of Neurogen Corporation in December 2009 (stock and cash consideration) and Metabasis Therapeutics in January 2010 (subsequent event).

Guidance, Outlook, Risks, and Contingencies

Outlook and Pipeline

• PROMACTA (GSK): Received FDA accelerated approval for ITP in Dec 2008 and positive EU opinion in Dec 2009. Expected to be a significant royalty driver in 2010.
• Bazedoxifene (Pfizer): Approved in EU for osteoporosis; FDA advisory committee expected. Combination product (Aprela) NDA expected H1 2010.
• Lasofoxifene (Pfizer): Approved in EU; FDA requested additional information. Pfizer exploring strategic options (out-licensing/sale).
• Internal Programs: SARMs (LGD-4033) in Phase I for muscle wasting; Glucagon receptor antagonists and Thyroid receptor beta agonists in preclinical/Phase I.

Risks and Contingencies

• IRS Audit: In Dec 2009, the IRS issued a Notice of Proposed Adjustment (NOPA) seeking a $71.5 million increase to 2007 taxable income and a $4.1 million penalty. Ligand recorded a $25.1 million FIN 48 liability and $3.0 million interest liability but disputes the findings. Unsuccessful negotiations could require payment of the penalty and utilization of net operating loss carryforwards.
• Revenue Concentration: Royalties from AVINZA and PROMACTA represented 21% and 74% of total revenues in 2009 and 2008, respectively. Setbacks in these products could materially impair results.
• Liquidity: Management believes current cash, investments, and royalty revenues are adequate to fund operations for at least the next 12 months. However, the company has an accumulated deficit of $681.6 million and may require additional financing.
• Investment Risk: One short-term investment in commercial paper (Golden Key Ltd.) is in default; the company estimates a recovery of $1.9 million on the $5.0 million investment.

Investor Verification Checklist

• IRS Dispute Resolution: Monitor the status of the IRS NOPA regarding the 2007 tax year to assess potential cash outflows ($4.1M penalty) and impact on NOL carryforwards.
• PROMACTA Commercialization: Verify GSK's sales performance and launch timeline in the EU and US to confirm royalty revenue projections for 2010.
• AVINZA Royalty Rate: Confirm the impact of the reduced 5% royalty rate on future cash flows compared to historical 15% rates.
• Lease Termination Payments: Track the scheduled payments of $14.3 million for the San Diego facility lease termination ($4.5M paid, $4.5M due July 2010, $5.3M due April 2011).
• Metabasis Integration: Review the financial impact and integration progress of the Metabasis acquisition (closed Jan 2010), specifically the Roche partnership for Hepatitis C.
• Golden Key Recovery: Monitor collection efforts on the defaulted $5.0 million commercial paper investment.